The best indicator for NiSource (NI)
We backtested 20 indicators across daily, weekly and hourly charts on real NiSource (NI) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 20/50 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for NiSource (NI) over ~53.5 years — trailing buy-and-hold by 0.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 20/50 Cross ✓ | Weekly | 7.9% | 0.57 | -44.2% | 68.8% | 16 | -0.1% |
| 2 | Donchian Breakout ✓ | Weekly | 5.7% | 0.48 | -57.2% | 44.4% | 36 | -2.3% |
| 3 | SMA 50/200 Cross ✓ | Daily | 6.2% | 0.45 | -64.7% | 44.7% | 38 | -1.8% |
| 4 | ADX / DMI ✓ | Weekly | 4.5% | 0.44 | -45.0% | 44.4% | 72 | -3.5% |
| 5 | EMA 50/200 Cross ✓ | Daily | 5.8% | 0.43 | -62.5% | 35.1% | 37 | -2.2% |
| 6 | Williams %R ✓ | Daily | 5.4% | 0.42 | -44.8% | 67.9% | 352 | -2.5% |
| 7 | Bollinger Mean-Reversion ✓ | Daily | 4.5% | 0.4 | -48.0% | 69.5% | 220 | -3.5% |
| 8 | RSI Trend (>50) ✓ | Weekly | 4.7% | 0.38 | -76.3% | 41.6% | 137 | -3.3% |
| 9 | Bollinger Breakout ✓ | Weekly | 3.4% | 0.37 | -61.9% | 54.9% | 51 | -4.6% |
| 10 | CCI ✓ | Daily | 4.4% | 0.35 | -56.7% | 70.0% | 253 | -3.6% |
| 11 | Stochastic ✓ | Daily | 3.8% | 0.33 | -51.5% | 71.4% | 248 | -4.2% |
| 12 | EMA 20/50 Cross ✓ | Daily | 3.7% | 0.32 | -82.5% | 32.3% | 130 | -4.3% |
| 13 | Rate of Change ✓ | Weekly | 3.0% | 0.27 | -81.6% | 48.0% | 173 | -5.0% |
| 14 | Holy Grail Confluence ✓ | Daily | 2.8% | 0.26 | -57.3% | 75.0% | 68 | -5.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For NiSource (NI), EMA 20/50 Cross on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.